114 related articles for article (PubMed ID: 18165112)
1. Medical treatment of Charcot neuroosteoarthropathy.
Jostel A; Jude EB
Clin Podiatr Med Surg; 2008 Jan; 25(1):63-9, vi-vii. PubMed ID: 18165112
[TBL] [Abstract][Full Text] [Related]
2. The diabetic Charcot foot.
Dissanayake SU; Bowling FL; Jude EB
Curr Diabetes Rev; 2012 May; 8(3):191-4. PubMed ID: 22429012
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates for the treatment of Charcot neuroarthropathy.
Anderson JJ; Woelffer KE; Holtzman JJ; Jacobs AM
J Foot Ankle Surg; 2004; 43(5):285-9. PubMed ID: 15480402
[TBL] [Abstract][Full Text] [Related]
4. Medical management of Charcot arthropathy.
Petrova NL; Edmonds ME
Diabetes Obes Metab; 2013 Mar; 15(3):193-7. PubMed ID: 22862834
[TBL] [Abstract][Full Text] [Related]
5. Interaction between IGF-1, inflammation, and neuropathy in the pathogenesis of acute charcot neuroarthropathy: lessons from alendronate therapy and future perspectives of medical therapy.
Pitocco D; Collina MC; Musella T; Ruotolo V; Caputo S; Manto A; Caradonna P; Galli M; Mancini L; Ghirlanda G
Horm Metab Res; 2008 Mar; 40(3):163-4. PubMed ID: 18256973
[No Abstract] [Full Text] [Related]
6. Acute Charcot arthropathy successfully treated with pamidronate: long-term follow-up.
Naqvi A; Cuchacovich R; Saketkoo L; Espinoza LR
Am J Med Sci; 2008 Feb; 335(2):145-8. PubMed ID: 18277124
[TBL] [Abstract][Full Text] [Related]
7. Charcot's foot: newest findings on its pathophysiology, diagnosis and treatment.
Molines L; Darmon P; Raccah D
Diabetes Metab; 2010 Sep; 36(4):251-5. PubMed ID: 20570543
[TBL] [Abstract][Full Text] [Related]
8. Treatment of acute Charcot foot with bisphosphonates: a systematic review of the literature.
Richard JL; Almasri M; Schuldiner S
Diabetologia; 2012 May; 55(5):1258-64. PubMed ID: 22361982
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of indolyl bisphosphonates as anti-bone resorptive and anti-leishmanial agents.
Singh US; Shankar R; Kumar A; Trivedi R; Chattopadhyay N; Shakya N; Palne S; Gupta S; Hajela K
Bioorg Med Chem; 2008 Sep; 16(18):8482-91. PubMed ID: 18752963
[TBL] [Abstract][Full Text] [Related]
10. [Bone fracture and the healing mechanisms. The effects of anti-resorptive agents on fracture healing].
Mashiba T; Mori S
Clin Calcium; 2009 May; 19(5):673-9. PubMed ID: 19398835
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in understanding the mechanism of action of bisphosphonates.
Coxon FP; Thompson K; Rogers MJ
Curr Opin Pharmacol; 2006 Jun; 6(3):307-12. PubMed ID: 16650801
[TBL] [Abstract][Full Text] [Related]
12. Medical treatment of otosclerosis: rationale for use of bisphosphonates.
Brookler K
Int Tinnitus J; 2008; 14(2):92-6. PubMed ID: 19205157
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of action of bisphosphonates: current status.
Roelofs AJ; Thompson K; Gordon S; Rogers MJ
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
[TBL] [Abstract][Full Text] [Related]
14. [New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].
Fukunaga M
Clin Calcium; 2009 Jan; 19(1):63-73. PubMed ID: 19122266
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates and atherosclerosis.
Fiore CE; Pennisi P; Pulvirenti I; Francucci CM
J Endocrinol Invest; 2009; 32(4 Suppl):38-43. PubMed ID: 19724165
[TBL] [Abstract][Full Text] [Related]
16. A review of bone metabolism and developments in medical treatment of the diabetic Charcot foot.
Jansen RB; Svendsen OL
J Diabetes Complications; 2018 Jul; 32(7):708-712. PubMed ID: 29857955
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis and medical management of diabetic Charcot neuroarthropathy.
Mascarenhas JV; Jude EB
Med Clin North Am; 2013 Sep; 97(5):857-72. PubMed ID: 23992897
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates beyond their anti-osteoclastic properties.
Varenna M
Rheumatology (Oxford); 2014 Jun; 53(6):965-7. PubMed ID: 24273023
[No Abstract] [Full Text] [Related]
19. Pharmacotherapy of bone metastases in breast cancer patients.
Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of osteoclasts does not prevent joint ankylosis in a mouse model of spondyloarthritis.
Lories RJ; Derese I; Luyten FP
Rheumatology (Oxford); 2008 May; 47(5):605-8. PubMed ID: 18334523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
